BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35287976)

  • 1. Review: HLA loss and detection in the setting of relapse from HLA-mismatched hematopoietic cell transplant.
    Arnold PY
    Hum Immunol; 2022 Oct; 83(10):712-720. PubMed ID: 35287976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant.
    Wu H; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Ouyang G; Xu X; Xiao H; Huang H; Zhao Y
    JAMA Netw Open; 2022 Apr; 5(4):e226114. PubMed ID: 35385089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide.
    Muñiz P; Kwon M; Carbonell D; Chicano M; Bailén R; Oarbeascoa G; Suárez-González J; Andrés-Zayas C; Menárguez J; Dorado N; Gómez-Centurión I; Anguita J; Díez-Martín JL; Martínez-Laperche C; Buño I
    Front Immunol; 2021; 12():642087. PubMed ID: 33841425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.
    Weisdorf DJ; Nelson G; Lee SJ; Haagenson M; Spellman S; Antin JH; Bolwell B; Cahn JY; Cervantes F; Copelan E; Gale R; Gratwohl A; Khoury HJ; McCarthy P; Marks DI; Szer J; Woolfrey A; Cortes-Franco J; Horowitz MM; Arora M;
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1475-8. PubMed ID: 19822308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.
    Baumeister SHC; Rambaldi B; Shapiro RM; Romee R
    Front Immunol; 2020; 11():191. PubMed ID: 32117310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation.
    Rovatti PE; Gambacorta V; Lorentino F; Ciceri F; Vago L
    Front Immunol; 2020; 11():147. PubMed ID: 32158444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.
    Bashey A; Solomon SR
    Bone Marrow Transplant; 2014 Aug; 49(8):999-1008. PubMed ID: 24842530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.
    Munchel AT; Kasamon YL; Fuchs EJ
    Best Pract Res Clin Haematol; 2011 Sep; 24(3):359-68. PubMed ID: 21925089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation.
    Ciceri F; Bonini C; Gallo-Stampino C; Bordignon C
    Cytotherapy; 2005; 7(2):144-9. PubMed ID: 16040393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current donor selection strategies for allogeneic hematopoietic cell transplantation.
    Timofeeva OA; Philogene MC; Zhang QJ
    Hum Immunol; 2022 Oct; 83(10):674-686. PubMed ID: 36038413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in allotransplant immunology.
    Barrett AJ; Rezvani K; Solomon S; Dickinson AM; Wang XN; Stark G; Cullup H; Jarvis M; Middleton PG; Chao N
    Hematology Am Soc Hematol Educ Program; 2003; ():350-71. PubMed ID: 14633790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of mismatched HLA in leukemia after stem-cell transplantation.
    Vago L; Perna SK; Zanussi M; Mazzi B; Barlassina C; Stanghellini MT; Perrelli NF; Cosentino C; Torri F; Angius A; Forno B; Casucci M; Bernardi M; Peccatori J; Corti C; Bondanza A; Ferrari M; Rossini S; Roncarolo MG; Bordignon C; Bonini C; Ciceri F; Fleischhauer K
    N Engl J Med; 2009 Jul; 361(5):478-88. PubMed ID: 19641204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
    Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of mismatched HLA in acute myeloid leukemia relapse after haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood: A case report.
    Han X; Zhao J; Liu J; Guo D; Li H; Fan S
    Transpl Immunol; 2022 Aug; 73():101602. PubMed ID: 35429620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Allogeneic hematopoietic stem cell transplantation for hematological malignancies: an algorithm for donor selection].
    Sugita J
    Rinsho Ketsueki; 2019; 60(6):626-634. PubMed ID: 31281155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.